VITROS 5600 chemistry analyzers with its associated reagents, supplies, and associated support
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Health Agency (DHA), on behalf of U.S. Naval Hospital Naples, Italy, has issued a Sources Sought Notice to conduct market research. The agency seeks to identify qualified vendors capable of providing two Ortho Clinical Diagnostics VITROS 5600 chemistry analyzers, along with associated reagents, supplies, and comprehensive support services. This effort aims to determine industry capability for a potential Firm Fixed Price (FFP) contract. Responses are due by June 30, 2026.
Scope of Work
The requirement includes the lease and full-risk maintenance of two VITROS 5600 chemistry analyzers. Key deliverables encompass application support, testing services, annual on-site training, and the provision of all necessary reagents and supplies. Technical specifications for the analyzers include operation without a water source, storage for over 20,000 samples, more than 120 on-board reagent positions, 10 user-defined chemistry channels, single-use tips, bi-directional interface with MHS Genesis LIS, 220V operation, and processing capabilities for manual, STAT, and automatic tests from primary tubes with Positive Sample Identification. A comprehensive validation study of green top tubes is also required within 30 days of contract execution.
Contract & Timeline
- Type: Sources Sought (potential Firm Fixed Price contract)
- NAICS Code: 325413, In Vitro Diagnostic Substance Manufacturing
- Place of Performance: U.S. Naval Hospital Naples, Italy
- Potential Duration: A base period of 12 months and four (4) 12-month option periods, totaling 60 months, with a possible 6-month extension under FAR 52.217-8.
- Set-Aside: None specified (market research)
- Responses Due: June 30, 2026, at 11:00 AM Eastern Time
- Questions Due: June 18, 2026, at 11:00 AM Eastern Time
- Published: June 11, 2026
Submission & Evaluation
Interested parties must submit a capabilities document, not exceeding five pages, via email to joshua.g.blickenstaff.civ@health.mil and stacy.m.ling.civ@health.mil. The document should detail the vendor's ability to meet the requirements outlined in the sample Performance Work Statement and include any other relevant information. This market research will inform the government's decision on a future acquisition strategy.
Additional Notes
This notice is for planning purposes only and does not guarantee a future solicitation. The government is not bound by the information provided and it is subject to change. All communications must be via email.